Oncopeptides AB Registered Shs News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

14.11.19	Extraordinary General Meeting in Oncopeptides AB (publ) (PR Newswire)
06.11.19	Oncopeptides to Highlight Data From Melflufen Clinical Program in Multiple Myeloma and AL Amyloidosis in Six Presentations at ASH Annual Meeting 2019 (PR Newswire)
06.11.19	Oncopeptides to Highlight Data From Melflufen Clinical Program in Multiple Myeloma and AL Amyloidosis in Six Presentations at ASH Annual Meeting 2019 (PR Newswire)
31.10.19	Number of Shares and Votes in Oncopeptides (PR Newswire)
31.10.19	Number of Shares and Votes in Oncopeptides (PR Newswire)
10.10.19	Nomination Committee Appointed in Respect of AGM 2020 in Oncopeptides (PR Newswire)
10.10.19	Nomination Committee Appointed in Respect of AGM 2020 in Oncopeptides (PR Newswire)
30.09.19	Number of Shares and Votes in Oncopeptides (PR Newswire)
30.09.19	Number of Shares and Votes in Oncopeptides (PR Newswire)
26.09.19	Patient Recruitment in the Pivotal Phase 2-Study HORIZON Completed (PR Newswire)
26.09.19	Patient Recruitment in the Pivotal Phase 2-Study HORIZON Completed (PR Newswire)
24.09.19	Exercise of Options and Sale of Shares Under the Employee Stock Option Program 2012/2019 (PR Newswire)
24.09.19	Exercise of Options and Sale of Shares Under the Employee Stock Option Program 2012/2019 (PR Newswire)
15.09.19	New Interim Data in RRMM Patients With Extramedullary Disease from the Pivotal Phase 2 Horizon-study Presented at International Myeloma Workshop (PR Newswire)
15.09.19	New Interim Data in RRMM Patients With Extramedullary Disease from the Pivotal Phase 2 Horizon-study Presented at International Myeloma Workshop (PR Newswire)
12.09.19	Data From Oncopeptides Melflufen Clinical Development Program Presented at SOHO 2019 Annual Meeting (PR Newswire)
12.09.19	Data From Oncopeptides Melflufen Clinical Development Program Presented at SOHO 2019 Annual Meeting (PR Newswire)
30.08.19	New Updated Data Will be Presented From Oncopeptides' Pivotal Phase 2 HORIZON Study in Patients With Extra Medullary Disease (EMD) on September 15th (PR Newswire)
30.08.19	New Updated Data Will be Presented From Oncopeptides' Pivotal Phase 2 HORIZON Study in Patients With Extra Medullary Disease (EMD) on September 15th (PR Newswire)
20.08.19	Oncopeptides Appoints Klaas Bakker as New Chief Medical Officer (PR Newswire)
20.08.19	Oncopeptides Appoints Klaas Bakker as New Chief Medical Officer (PR Newswire)
16.08.19	Oncopeptides Announces Acceptance of Data for Presentation at International Myeloma Workshop, September 12-15 (PR Newswire)
16.08.19	Oncopeptides Announces Acceptance of Data for Presentation at International Myeloma Workshop, September 12-15 (PR Newswire)
31.07.19	Number of Shares and Votes in Oncopeptides (PR Newswire)
31.07.19	Number of Shares and Votes in Oncopeptides (PR Newswire)
28.06.19	Oncopeptides has Completed a Directed Share Issue of Approximately SEK 727 Million (PR Newswire)
27.06.19	Oncopeptides Intends to Make a Directed Share issue (PR Newswire)
16.06.19	New Data Presented from Oncopeptides' Pivotal Phase 2 HORIZON Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma at 24th EHA Congress (PR Newswire)
16.06.19	New Data Presented from Oncopeptides' Pivotal Phase 2 HORIZON Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma at 24th EHA Congress (PR Newswire)
14.06.19	New Data Presented at 24th EHA Congress From Oncopeptides' Phase 1/2 ANCHOR Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma (RRMM) (PR Newswire)
14.06.19	New Data Presented at 24th EHA Congress From Oncopeptides' Phase 1/2 ANCHOR Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma (RRMM) (PR Newswire)
13.06.19	Oncopeptides Will Host a Webcast on Monday, 17 June at 09:00 (CET) to Review and Update Presentations From European Hematology (EHA) Meeting (PR Newswire)
13.06.19	Oncopeptides Will Host a Webcast on Monday, 17 June at 09:00 (CET) to Review and Update Presentations From European Hematology (EHA) Meeting (PR Newswire)
03.06.19	New Data from Oncopeptides Phase 1/2 O-12-M1 Trial Evaluating Melflufen in RRMM Presented at 2019 ASCO Annual Meeting (PR Newswire)
03.06.19	New Data from Oncopeptides Phase 1/2 O-12-M1 Trial Evaluating Melflufen in RRMM Presented at 2019 ASCO Annual Meeting (PR Newswire)
21.05.19	Bulletin From The Annual General Meeting in Oncopeptides Ab (publ) (PR Newswire)
21.05.19	Bulletin From The Annual General Meeting in Oncopeptides Ab (publ) (PR Newswire)
21.05.19	Oncopeptides AB: INTERIM REPORT Q1 2019 (PR Newswire)
21.05.19	Oncopeptides AB: INTERIM REPORT Q1 2019 (PR Newswire)
20.05.19	Oncopeptides to Apply for Accelerated Approval in the US (PR Newswire)
16.05.19	Oncopeptides Announces Acceptance of Four Abstracts Highlighting Melflufen Clinical Programs for Presentation at 24th EHA Congress in June 2019 (PR Newswire)
16.05.19	Oncopeptides Announces Acceptance of Four Abstracts Highlighting Melflufen Clinical Programs for Presentation at 24th EHA Congress in June 2019 (PR Newswire)
16.05.19	Oncopeptides Announces Melflufen Data Accepted for Presentation at 2019 ASCO Annual Meeting (PR Newswire)
16.05.19	Oncopeptides Announces Melflufen Data Accepted for Presentation at 2019 ASCO Annual Meeting (PR Newswire)
24.04.19	Oncopeptides Provides New Guidance on the Patient Recruitment in the OCEAN Study and a Clinical Program Update in a Webcast at 10:00 (CET) (PR Newswire)
24.04.19	Oncopeptides Provides New Guidance on the Patient Recruitment in the OCEAN Study and a Clinical Program Update in a Webcast at 10:00 (CET) (PR Newswire)
16.04.19	Annual General Meeting in Oncopeptides AB (publ) (PR Newswire)
16.04.19	Annual General Meeting in Oncopeptides AB (publ) (PR Newswire)
11.04.19	Oncopeptides AB: Updated Financial Calendar (PR Newswire)
11.04.19	Oncopeptides AB: Updated Financial Calendar (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

ABB	50.28	1.62 %	K V
UBS Group	28.48	1.42 %	K V
CieFinRichemont	122.70	1.24 %	K V
Lonza Grp	526.40	1.15 %	K V
Part Grp Hldg	1’280.00	1.11 %	K V
Sonova Hldg	300.80	-0.07 %	K V
Sika	228.10	-0.09 %	K V
Novartis	93.27	-0.12 %	K V
Nestle	76.48	-0.21 %	K V
Swisscom	508.50	-0.29 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Oncopeptides AB Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten